BioAge Labs, Inc.
BIOAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioAge Labs, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. With a market capitalization of $440.2M, it sits in small-cap territory. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Market Cap
$440.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.06
EPS (TTM)
$-2.39
EPS (Fwd)
$-2.36
ROE
-28.2%
ROA
-18.5%
Cash
$318.7M
Total Debt
$2.8M
Free CF
-$58.1M
52W Change
88.4%
Annual Financials
Cash vs Debt
Where BIOA stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, BIOA finished 46.32% below its 150-day moving average ($18.33) and 41.64% below its 200-day moving average ($16.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIOA overbought or oversold?
At the August 27, 2026 close, BIOA's RSI(14) was 35.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $318.7M in cash comfortably exceeding the $2.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$58.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -28.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, BIOA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIOA.